Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist

Details for Australian Patent Application No. 2006331770 (hide)

Owner Schering Corporation

Inventors Davis Jr., Harry; Van Heek, Margaret; Hwa, Joyce J.

Agent Griffith Hack

Pub. Number AU-A-2006331770

PCT Pub. Number WO2007/075702

Priority 60/787,048 29.03.06 US; 60/836,642 09.08.06 US; 60/855,178 30.10.06 US; 60/752,710 21.12.05 US

Filing date 19 December 2006

Wipo publication date 5 July 2007

International Classifications

A61K 31/397 (2006.01) - having four-membered rings, e.g. azetidine

A61K 31/445 (2006.01) - Non-condensed piperidines, e.g. piperocaine

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

Event Publications

10 July 2008 PCT application entered the National Phase

  PCT publication WO2007/075702 Priority application(s): WO2007/075702

12 July 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006331775-Affinity optimized EphA2 agonistic antibodies and methods of use thereof

2006331765-Substituted isoquinoline1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor